Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.

The mechanistic target of rapamycin (mTOR) is an established therapeutic target in renal cell carcinoma (RCC). Mechanisms of secondary resistance to rapalog therapy in RCC have not been studied previously. We identified six patients with metastatic RCC who initially responded to mTOR inhibitor thera...

Full description

Bibliographic Details

Published in:	PLoS Genetics
Main Authors:	Lana Hamieh, Toni K Choueiri, Barbara Ogórek, Damir Khabibullin, Daniel Rosebrock, Dimitri Livitz, Andre Fay, Jean-Christophe Pignon, David F McDermott, Neeraj Agarwal, Wenhua Gao, Sabina Signoretti, David J Kwiatkowski
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2018-09-01
Online Access:	http://europepmc.org/articles/PMC6181431?pdf=render